1
|
De Carlo A, Ronchi D, Piastra M, Tosca EM, Magni P. Predicting ADMET Properties from Molecule SMILE: A Bottom-Up Approach Using Attention-Based Graph Neural Networks. Pharmaceutics 2024; 16:776. [PMID: 38931898 PMCID: PMC11207804 DOI: 10.3390/pharmaceutics16060776] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2024] [Revised: 05/08/2024] [Accepted: 05/30/2024] [Indexed: 06/28/2024] Open
Abstract
Understanding the pharmacokinetics, safety and efficacy of candidate drugs is crucial for their success. One key aspect is the characterization of absorption, distribution, metabolism, excretion and toxicity (ADMET) properties, which require early assessment in the drug discovery and development process. This study aims to present an innovative approach for predicting ADMET properties using attention-based graph neural networks (GNNs). The model utilizes a graph-based representation of molecules directly derived from Simplified Molecular Input Line Entry System (SMILE) notation. Information is processed sequentially, from substructures to the whole molecule, employing a bottom-up approach. The developed GNN is tested and compared with existing approaches using six benchmark datasets and by encompassing regression (lipophilicity and aqueous solubility) and classification (CYP2C9, CYP2C19, CYP2D6 and CYP3A4 inhibition) tasks. Results show the effectiveness of our model, which bypasses the computationally expensive retrieval and selection of molecular descriptors. This approach provides a valuable tool for high-throughput screening, facilitating early assessment of ADMET properties and enhancing the likelihood of drug success in the development pipeline.
Collapse
Affiliation(s)
| | | | | | | | - Paolo Magni
- Dipartimento di Ingegneria Industriale e dell’Informazione, Università degli Studi di Pavia, 27100 Pavia, Italy; (A.D.C.); (D.R.); (M.P.); (E.M.T.)
| |
Collapse
|
2
|
Incecayir T, Demir ME. In Vivo Relevance of a Biphasic In Vitro Dissolution Test for the Immediate Release Tablet Formulations of Lamotrigine. Pharmaceutics 2023; 15:2474. [PMID: 37896234 PMCID: PMC10610453 DOI: 10.3390/pharmaceutics15102474] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2023] [Revised: 10/07/2023] [Accepted: 10/12/2023] [Indexed: 10/29/2023] Open
Abstract
Biphasic in vitro dissolution testing is an attractive approach to reflect on the interplay between drug dissolution and absorption for predicting the bioperformance of drug products. The purpose of this study was to investigate the in vivo relevance of a biphasic dissolution test for the immediate release (IR) formulations of a Biopharmaceutics Classification System (BCS) Class II drug, lamotrigine (LTG). The biphasic dissolution test was performed using USP apparatus II with the dual paddle modification. A level A in vitro-in vivo correlation (IVIVC) was constructed between the in vitro partition into the octanol and absorption data of the reference product. A good relation between in vitro data and absorption was obtained (r2 = 0.881). The one-compartment open model was introduced to predict the human plasma profiles of the test product. The generic product was found to be bioequivalent to the original product in terms of 80-125% bioequivalence (BE) criteria (85.9-107% for the area under the plasma concentration curve (AUC) and 82.7-97.6% for the peak plasma concentration (Cmax) with a 90% confidence interval (CI)). Overall, it was revealed that the biphasic dissolution test offers a promising ability to estimate the in vivo performance of IR formulations of LTG, providing considerable time and cost savings in the development of generic drug products.
Collapse
Affiliation(s)
- Tuba Incecayir
- Department of Pharmaceutical Technology, Faculty of Pharmacy, Gazi University, 06330 Ankara, Turkey
| | | |
Collapse
|
3
|
Krajcar D, Jereb R, Legen I, Opara J, Grabnar I. Predictive Potential of Acido-Basic Properties, Solubility and Food on Bioequivalence Study Outcome: Analysis of 128 Studies. Drugs R D 2023; 23:211-220. [PMID: 37300755 PMCID: PMC10439087 DOI: 10.1007/s40268-023-00426-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/18/2023] [Indexed: 06/12/2023] Open
Abstract
BACKGROUND AND OBJECTIVES Risk assessment related to bioequivalence study outcome is critical for effective planning from the early stage of drug product development. The objective of this research was to evaluate the associations between solubility and acido-basic parameters of an active pharmaceutical ingredient (API), study conditions and bioequivalence outcome. METHODS We retrospectively analyzed 128 bioequivalence studies of immediate-release products with 26 different APIs. Bioequivalence study conditions and acido-basic/solubility characteristics of APIs were collected and their predictive potential on the study outcome was assessed using a set of univariate statistical analyses. RESULTS There was no difference in bioequivalence rate between fasting and fed conditions. The highest proportion of non-bioequivalent studies was for weak acids (10/19 cases, 53%) and neutral APIs (23/95 cases, 24%). Lower non-bioequivalence occurrence was observed for weak bases (1/15 cases, 7%) and amphoteric APIs (0/16 cases, 0%). The median dose numbers at pH 1.2 and pH 3 were higher and the most basic acid dissociation constant (pKa) was lower in the non-bioequivalent group of studies. Additionally, APIs with low calculated effective permeability (cPeff) or low calculated lipophilicity (clogP) had lower non-bioequivalence occurrence. Results of the subgroup analysis of studies under fasting conditions were similar as for the whole dataset. CONCLUSION Our results indicate that acido-basic properties of API should be considered in bioequivalence risk assessment and reveal which physico-chemical parameters are most relevant for the development of bioequivalence risk assessment tools for immediate-release products.
Collapse
Affiliation(s)
- Dejan Krajcar
- Lek Pharmaceuticals d.d., A Sandoz Company, Verovskova 57, 1526, Ljubljana, Slovenia.
- Faculty of Pharmacy, University of Ljubljana, Aškerčeva cesta 7, 1000, Ljubljana, Slovenia.
| | - Rebeka Jereb
- Lek Pharmaceuticals d.d., A Sandoz Company, Verovskova 57, 1526, Ljubljana, Slovenia
| | - Igor Legen
- Lek Pharmaceuticals d.d., A Sandoz Company, Verovskova 57, 1526, Ljubljana, Slovenia
| | - Jerneja Opara
- Lek Pharmaceuticals d.d., A Sandoz Company, Verovskova 57, 1526, Ljubljana, Slovenia
| | - Iztok Grabnar
- Faculty of Pharmacy, University of Ljubljana, Aškerčeva cesta 7, 1000, Ljubljana, Slovenia
| |
Collapse
|
4
|
Mahmood A, Erum A, Tulain UR, Malik NS, Saleem A, Alqahtani MS, Malik MZ, Siddiqui M, Safdar A, Malik A. Exploring the gelling properties of Plantago ovata-based Arabinoxylan: Fabrication and optimization of a topical emulgel using response surface methodology. PLoS One 2023; 18:e0290223. [PMID: 37607173 PMCID: PMC10443879 DOI: 10.1371/journal.pone.0290223] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2023] [Accepted: 08/04/2023] [Indexed: 08/24/2023] Open
Abstract
Prime objective of the current research was to develop a stable nimesulide emulgel with the help of arabinoxylan, a natural gelling agent extracted from Plantago ovata. The response surface methodology was used by a Design Expert 10 software to formulate and optimize the emulgel. The experimental design approach evaluated the impact of independent and dependent variables. Independent variables were different concentrations of arabinoxylan, span 80 and tween 20, whereas, dependent variables were viscosity, pH, and content uniformity. FTIR demonstrated the compatibility of nimesulide with the excipients. Stability study indicated no phase separation and no change in pH for formulation F1, F3 and F4. The negative values of zeta potential revealed the excellent stability of emulgel. Viscosity, spreadability and extrudability values were in desired range. Ex-vivo permeation study illustrated 86%, 55% and 66% release of the drug over a period of 24 h from the formulations F1, F3 and F4, respectively. Analgesic effect of the optimized emulgel was significantly higher in test group as compared to control and did not produce any sort of irritation. Therefore, it can be concluded that the newly developed emulgel based on arabinoxylan, as gelling agent, appear to be an effective drug delivery system.
Collapse
Affiliation(s)
- Arshad Mahmood
- College of Pharmacy, Al Ain University, Abu Dhabi, UAE
- AAU Health and Biomedical Research Center (HBRC) Al Ain University, Abu Dhabi, UAE
| | - Alia Erum
- Faculty of Pharmacy, University of Sargodha, Sargodha, Pakistan
| | | | - Nadia Shamshad Malik
- Faculty of Pharmacy, Capital University of Science and Technology, Islamabad, Pakistan
| | - Aneeqa Saleem
- Faculty of Pharmacy, University of Sargodha, Sargodha, Pakistan
| | - Mohammed S. Alqahtani
- Department of Pharmaceutics, Nanobiotechnology Unit, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia
| | | | - Mahwish Siddiqui
- Faculty of Pharmacy, Capital University of Science and Technology, Islamabad, Pakistan
| | - Asif Safdar
- Faculty of Pharmacy, Capital University of Science and Technology, Islamabad, Pakistan
| | - Abdul Malik
- Faculty of Pharmacy, University of Sargodha, Sargodha, Pakistan
| |
Collapse
|
5
|
Usta DY, Incecayir T. Modeling of In Vitro Dissolution Profiles of Carvedilol Immediate-Release Tablets in Different Dissolution Media. AAPS PharmSciTech 2022; 23:201. [PMID: 35882662 DOI: 10.1208/s12249-022-02355-0] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2022] [Accepted: 07/06/2022] [Indexed: 11/30/2022] Open
Abstract
Quantitative evaluation of drug dissolution characteristics based on mathematical models is essential to understand and predict a particular drug release profile. In this study, model-dependent evaluation of the dissolution kinetics of reference and five test products (25-mg, immediate-release (IR) tablets) of an antihypertensive drug, carvedilol, was carried out using the DDSolver® program. The effects of pH (pH 1.2, 4.5, and 6.8) and various media with/without 0.5% (w/v) anionic, cationic, and nonionic surfactants (sodium lauryl sulfate (SLS), hexadecyltrimethylammonium bromide (CTAB), and polysorbate 80) on the dissolution kinetics of the bioequivalent IR products of carvedilol were investigated. The Weibull-1 model was fitted successfully to the dissolution data of all products at pH 1.2 and pH 4.5, as well as in the pH 6.8 medium with CTAB according to the model goodness of fit (r2 = 0.981-0.999, AIC = 14.5-42.6, MSC = 1.99-5.25). Model fitting produced good fits to Gompertz-1 for all products at pH 6.8 without a surfactant (r2 = 0.975-0.998, AIC = 28.3-55, MSC = 2.53-5.82). For pH 6.8 media containing SLS or polysorbate 80, Logistic-2 was fitted successfully to the dissolution data of all products (r2 = 0.974-0.999, AIC = 20.9-52.1, MSC = 1.90-5.69). Overall, the model-dependent analysis of in vitro dissolution data indicated in vitro equivalence of the reference and test products of carvedilol in each medium in terms of kinetic models, suggesting that it would have an important role in developing generic drug products of the BCS class II drug carvedilol.
Collapse
Affiliation(s)
- Duygu Yilmaz Usta
- Department of Pharmaceutical Technology, Faculty of Pharmacy, Gazi University, Etiler, 06330, Ankara, Turkey
| | - Tuba Incecayir
- Department of Pharmaceutical Technology, Faculty of Pharmacy, Gazi University, Etiler, 06330, Ankara, Turkey.
| |
Collapse
|
6
|
Raloxifene-loaded SLNs with enhanced biopharmaceutical potential: QbD-steered development, in vitro evaluation, in vivo pharmacokinetics, and IVIVC. Drug Deliv Transl Res 2021; 12:1136-1160. [PMID: 33966178 DOI: 10.1007/s13346-021-00990-x] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/22/2021] [Indexed: 12/13/2022]
Abstract
Raloxifene hydrochloride, a second-generation selective estrogen receptor modulator, has been approved for the management of breast cancer. However, it is known to exhibit poor (~ 2%) and inconsistent oral bioavailability in humans, primarily ascribable to its low aqueous solubility, extensive first-pass metabolism, P-gp efflux, and presystemic glucuronide conjugation. The present research work entails the systematic development and evaluation of SLNs of RLX for its enhanced biopharmaceutical performance against breast cancer. Factor screening studies were conducted using Taguchi design, followed by optimization studies employing Box-Behnken design. Preparation of SLNs was carried out using glyceryl monostearate and Compritol® 888 ATO (i.e., lipid), Phospholipid S-100 (i.e., co-surfactant), and TPGS-1000 (i.e., surfactant) employing solvent diffusion method. The optimized formulation was evaluated for zeta potential, average particle size, field emission scanning electron microscope, transmission electron microscopy, and in vitro release study. Further, MCF-7 cells (cell cytotoxicity assay, apoptosis assay, and reactive oxygen species assay) and Caco-2 cells (cell uptake studies and P-gp efflux assay) were employed to evaluate the in vitro anticancer potential of the developed optimized formulation. In vivo pharmacokinetic studies were conducted in Sprague-Dawley rats to evaluate the therapeutic profile of the developed formulation. The optimized SLN formulations exhibited a mean particle size of 109.7 nm, PDI 0.289 with a zeta potential of - 13.7 mV. In vitro drug dissolution studies showed Fickian release, with release exponent of 0.137. Cell cytotoxicity assay, apoptosis assay, and cellular uptake indicated 6.40-, 5.40-, and 3.18-fold improvement in the efficacy of RLX-SLNs vis-à-vis pure RLX. Besides, the pharmacokinetic studies indicated quite significantly improved biopharmaceutical performance of RLX-SLNs vis-à-vis pure drug, with 4.06-fold improvement in Cmax, 4.40-fold in AUC(0-72 h), 4.56-fold in AUC(0-∞), 1.53-fold in Ka, 2.12-fold in t1/2, and 1.22-fold in Tmax. Further, for RLX-SLNs and pure drug, high degree of level A linear correlation was established between fractions of drug dissolved (in vitro) and of drug absorbed (in vivo) at the corresponding time-points. Stability studies indicated the robustness of RLX-SLNs when stored at for 3 months. Results obtained from the different studies construe promising the anticancer potential of the developed RLX-SLNs, thereby ratifying the lipidic nanocarriers as an efficient drug delivery strategy for improving the biopharmaceutical attributes of RLX.
Collapse
|